DALLAS / May 04, 2023 / Business Wire / Sonida Senior Living, Inc. (NYSE: SNDA) (“Sonida” or “the Company”) announced today that it will issue its First Quarter 2023 earnings release before the market opens for trading on the New York Stock Exchange on Thursday, May 11, 2023. A conference call to discuss those earnings will be held on Thursday, May 11, 2023, at 12:30 p.m. Eastern Time.
The call-in number for the conference call is 877-407-0989 (no passcode required). A link to a simultaneous webcast of the teleconference will be available here through Windows Media Player or RealPlayer.
The conference call will be recorded and available for replay starting May 12, 2023, through May 26, 2023. To access the conference call replay, call 877-660-6853, passcode 13738670.
About Sonida Senior Living
Dallas-based Sonida Senior Living, Inc. is a leading owner-operator of independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 72 senior housing communities in 18 states with an aggregate capacity of approximately 8,000 residents, including 62 communities which the Company owns and 10 communities that the Company manages on behalf of third parties.
For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, Twitter or LinkedIn.
Last Trade: | US$23.08 |
Daily Volume: | 0 |
Market Cap: | US$440.140M |
August 15, 2024 August 12, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB